Cancer Immunology Reserch

TIME for Endometrial Cancer: Advancements and Challenges in Therapeutic Targets for the Endometrial Cancer Tumor Immune Microenvironment

by

Cancer Immunol Res. 2025 Nov 7:OF1-OF17. doi: 10.1158/2326-6066.CIR-25-0438. Online ahead of print. ABSTRACT Endometrial cancer is the sixth most common cancer in women worldwide and the fourth most common cancer in women in the United States. In the United States, its incidence and mortality rates have continued to increase since the late 1990s. Endometrial cancer … Read more

RAS(ON) multi-selective inhibition drives antitumor immunity in preclinical models of NRAS-mutant melanoma

by

Cancer Immunol Res. 2025 Nov 4. doi: 10.1158/2326-6066.CIR-25-0744. Online ahead of print. ABSTRACT Targeted therapies for NRAS-mutant melanoma remain an unmet clinical need. Here, we demonstrate that RMC-7977, a preclinical RAS(ON) multi-selective inhibitor representative of the investigational agent daraxonrasib (RMC-6236), was able to elicit potent antitumor immune responses across multiple NRAS-mutant melanoma models. Treatment with … Read more

IL4/IL13 inhibition via dupilumab reduces malignant T cell proliferation and promotes antitumor immunity in Sezary syndrome

by

Cancer Immunol Res. 2025 Oct 29. doi: 10.1158/2326-6066.CIR-25-0677. Online ahead of print. ABSTRACT Patients with Sezary syndrome (SS), the aggressive leukemic variant of cutaneous T cell lymphoma (CTCL), have few therapeutic options and a poor prognosis. We previously showed that the IL4/IL13 signaling pathway impacts SS tumorigenesis. Here, we investigated the potential therapeutic effect of … Read more

Downregulation of HLA Class I Expression Through HLA-A DNA Methylation Is Associated with Reduced CD8+ T Cell Infiltration in Cervical Cancer

by

Cancer Immunol Res. 2025 Oct 27. doi: 10.1158/2326-6066.CIR-25-0594. Online ahead of print. ABSTRACT Human leukocyte antigen class I (HLA-I) is central to tumor immune recognition, but its regulatory mechanisms in cervical cancer remain poorly understood. This study aimed to elucidate the impact of HLA-I regulatory mechanisms on CD8+ T cell infiltration and identify distinct histotype-specific … Read more

Altered thymopoiesis in thymoma is associated with defects in negative selection machinery and decreased Treg abundance

by

Cancer Immunol Res. 2025 Oct 27. doi: 10.1158/2326-6066.CIR-25-0190. Online ahead of print. ABSTRACT Thymomas are rare thymic epithelial tumors harboring a high but variable proportion of lymphocytes without obvious function. Autoimmunity is present in one third of patients at diagnosis. Herein, we performed a phenotypic, single-cell RNA sequencing (scRNAseq), and spatial analysis of both the … Read more

Circulating neoantigen- and viral oncoprotein-specific CD8+ T cells share a transcriptional signature

by

Cancer Immunol Res. 2025 Oct 23. doi: 10.1158/2326-6066.CIR-25-0082. Online ahead of print. ABSTRACT Tumor-specific CD8+ T cells in blood appear to be important for and predictive of response to anti-PD-1 therapies. However, as most tumor antigens are unique to a given patient, identification of tumor-specific CD8+ T cells is not routinely feasible. Here, we characterized … Read more

Targeting SALL4 with an HLA Class I-restricted TCR for cancer immunotherapy

by

Cancer Immunol Res. 2025 Oct 20. doi: 10.1158/2326-6066.CIR-24-0207. Online ahead of print. ABSTRACT Aberrant expression of the oncogene SALL4 is associated with stemness, more aggressive cancer phenotype, and reduced patient survival in various tumor types making SALL4 a potential target for cancer immunotherapy. We conducted a transcriptional analysis of SALL4 expression in colorectal cancer (CRC) … Read more

HNRNPA2B1 orchestrates immune evasion in colorectal cancer by rewiring tumor-immune cell interactions and suppressing CD8+ T cell infiltration

by

Cancer Immunol Res. 2025 Oct 20. doi: 10.1158/2326-6066.CIR-25-0433. Online ahead of print. ABSTRACT Immune checkpoint blockade (ICB) has transformed colorectal cancers (CRCs) therapy, yet the majority of microsatellite-stable (MSS) CRCs remain refractory due to insufficient tumor-immune cell crosstalk. Identifying molecular regulators that modulate the tumor immune microenvironment (TIME) is crucial for expanding ICB efficacy. Here, … Read more

deneme bonusu veren siteler - canlı bahis siteleri - casino siteleri casino siteleri deneme bonusu veren siteler canlı casino siteleri error code: 520